LEO 153339
Alternative Names: LEO-153339Latest Information Update: 28 Jun 2025
At a glance
- Originator LEO Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for preclinical development in Unspecified in Denmark
- 12 May 2021 Preclinical trials in Unspecified in Denmark (unspecified route)
- 12 May 2021 LEO Pharma plans a phase I trial (in volunteers) (NCT04883333) (EudraCT 2020-005748-51)